Ignet

Gene Information

Gene symbol: CEACAM5

Gene name: carcinoembryonic antigen-related cell adhesion molecule 5

HGNC ID: 1817

Synonyms: CD66e

Related Genes

#	Gene Symbol	Number of hits
1	ACPP	1 hits
2	AFP	1 hits
3	ALB	1 hits
4	ALPI	1 hits
5	AMACR	1 hits
6	ATHS	1 hits
7	B3GAT1	1 hits
8	CCND1	1 hits
9	CD247	1 hits
10	CD68	1 hits
11	CGB	1 hits
12	CGB5	1 hits
13	DES	1 hits
14	ERBB2	1 hits
15	ETFA	1 hits
16	HBB	1 hits
17	KIT	1 hits
18	KLK3	1 hits
19	KRT19	1 hits
20	KRT20	1 hits
21	KRT5	1 hits
22	KRT7	1 hits
23	KRT8	1 hits
24	MME	1 hits
25	MUC1	1 hits
26	MUC2	1 hits
27	MUC5AC	1 hits
28	MUC6	1 hits
29	NCAM1	1 hits
30	PDGFB	1 hits
31	PDGFRA	1 hits
32	PGR	1 hits
33	PLAT	1 hits
34	S100A1	1 hits
35	TP53	1 hits
36	TP63	1 hits
37	VIM	1 hits

Related Sentences

#	PMID	Sentence
1	1854615	Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
2	1854615	The usefulness of post-operatively serial serum CA15-3 determination with CEA and TPA was evaluated in a group of 285 breast cancer patients.
3	1854615	In most of them, elevated values of one or more tumour markers were the first pathological sign and CA15-3, CEA and TPA sensitivity to 'early' diagnosis of metastases were 46%, 7% and 63% respectively.
4	1854615	In metastatic patients, no organ-specificity was shown either by CA15-3 or by CEA and TPA.
5	1854615	Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
6	1854615	The usefulness of post-operatively serial serum CA15-3 determination with CEA and TPA was evaluated in a group of 285 breast cancer patients.
7	1854615	In most of them, elevated values of one or more tumour markers were the first pathological sign and CA15-3, CEA and TPA sensitivity to 'early' diagnosis of metastases were 46%, 7% and 63% respectively.
8	1854615	In metastatic patients, no organ-specificity was shown either by CA15-3 or by CEA and TPA.
9	1854615	Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
10	1854615	The usefulness of post-operatively serial serum CA15-3 determination with CEA and TPA was evaluated in a group of 285 breast cancer patients.
11	1854615	In most of them, elevated values of one or more tumour markers were the first pathological sign and CA15-3, CEA and TPA sensitivity to 'early' diagnosis of metastases were 46%, 7% and 63% respectively.
12	1854615	In metastatic patients, no organ-specificity was shown either by CA15-3 or by CEA and TPA.
13	1854615	Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
14	1854615	The usefulness of post-operatively serial serum CA15-3 determination with CEA and TPA was evaluated in a group of 285 breast cancer patients.
15	1854615	In most of them, elevated values of one or more tumour markers were the first pathological sign and CA15-3, CEA and TPA sensitivity to 'early' diagnosis of metastases were 46%, 7% and 63% respectively.
16	1854615	In metastatic patients, no organ-specificity was shown either by CA15-3 or by CEA and TPA.
17	2090796	In a group of breast cancer patients post-operatively followed-up by serum CEA, TPA, and CA15-3 level determinations, the CA549, CA M26 and CA M29 values as well were measured.
18	2173835	Staging included: case history, physical examination, full blood count, biochemical tests (alkaline phosphatase, SGOT, GGTP, LDH), CEA, X-ray assessment including CT scan of the chest, bronchoscopy, peritoneoscopy, liver scan (US was not routinely used at the beginning), bilateral bone marrow trephine biopsy, and bone scan.
19	3443433	Corpuscular zinc concentrations had a significant positive correlation with platelet counts, CEA, ALP and LDH, and a significant negative correlation with hemoglobin concentration and GSH-Px.
20	3867765	[Relation of diabetic markers and tumor markers--hemoglobin A1, glycosylated albumin, glycosylated protein and CEA, CA19-9 in diabetic and cancerous patients].
21	6201769	While, serum carcinoembryonic antigen (CEA) and human chorionic gonadotropin (HCG) were in normal range.
22	7686362	Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
23	7686362	Serum TPS values were compared with respective blood prostate specific antigen (PSA), prostatic acid phosphatase (PAP), carcinoembryonic antigen (CEA) and testosterone levels in a retrospective manner.
24	7686362	Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
25	7686362	Serum TPS values were compared with respective blood prostate specific antigen (PSA), prostatic acid phosphatase (PAP), carcinoembryonic antigen (CEA) and testosterone levels in a retrospective manner.
26	11960290	The cIgTCR was constructed of a CEA-specific humanized single-chain Fv antibody fragment fused to the IgG1 Fc domain and the CD3 zeta chain.
27	20445731	Ca 19.9, CEA, AFP and PSA negative.
28	22076171	Immunohistochemical results of the tumor were as follows: α-methylacyl-coenzyme A rasemase (AMACR) +++, vimentin +++, cytokeratin (CK) 18 +++, CD10 +++, S-100 protein +, MUC1 ++, MUC2 ++, MUC5AC ++, MUC6 ++, panCK Cam5.2 +, CK7 +, CK8 +, CK14 +, CK19 +, CK20 +, p53 +, HepPar1 +, CD68 +, platelet-derived growth factor-α (PDGFRA) +, PanCK AE1/3 -, PanCK WSS -, PanCK MNF115 -, CK 35BE12 -, CK5/6 -, EMA -, desmin -, smooth muscle antigen -, α-fetoprotein -, CEA -, estrogen receptor -, progesterone receptor -, HER2 -, p63 -, and KIT -.
29	22076171	These results suggest that OPRCC can express colloidal iron, low molecular weight CKs, S100 protein, MUC1, MUC2, MUC5AC, MUC6, p53, PDGFRA, and HepPar1.
30	23638232	Immunohistochemically, the lymphoid cells were positive for vimentin, CD3, CD4, CD5, CD8, CD10, CD15, CD20, CD23, CD30, CD43, CD38, CD138, CD45RO, CD79α, bcl-2, bcl-6, κ-chain, λ-chain, and Ki-67 (labeling index=7%).
31	23638232	The lymphoblastic cells were positively labeled for CD15 and CD30.
32	23638232	They were negative for cytokeratin (CK) CAM5.2, CKAE1/3, CK34BE12, CK5/6, CK7, CK8, CK18, CK19, CK20, EMA, CEA, CD56, CD57, p53, KIT, PDGFRA, and cyclin D1.
33	23638232	The low Ki-67 labeling and negative p53 also suggested the diagnosis.